Tracking Cardiac Health Over Time

Numerous red flags on CPET, including severely reduced Peak VO₂ with reduced AT, low peak stroke volume with a decreasing trend, hypotensive BP response and pulmonary congestion, supported urgent coronary angiography that revealed near-total occlusion of the left main coronary artery. The patient went straight to bypass surgery and bypassed a disastrous event

Even highly active individuals with high baseline Peak VO₂ can have subclinical ischemic heart disease, and aggressive high-volume, high-intensity exercise in these circumstances may make the problem worse, not better. Reviewing all CPET parameters in a medically comprehensive manner is critical for quality of life and outcomes

CPET can identify mechanical dysfunction that precedes electrical changes on stress ECG. This high-risk CPET case had no ECG changes, but the patient was found to have severe triple-vessel disease with balanced ischemia. Serial CPET will be key to clinician-guided long-term recovery

Serial CPET documented a significant increase in ischemic burden after two years, now accompanied by new symptoms. The case shows how repeat physiologic testing can identify coronary disease progression before follow-up becomes reactive

After MI with non-obstructive CAD, CPET showed reduced Peak VO₂ and a cardiac dysfunction pattern consistent with functionally significant microvascular ischemic heart disease. Because PCI was not an option, the case highlights ExRx and aggressive medical therapy as the actionable path for clinician-guided recovery

Eleven months after starting Repatha (PCSK9i) as part of aggressive lipid-lowering therapy, repeat CPET showed a 28% rise in Peak VO₂. The case demonstrates how serial CPET can quantify functional response to risk-modification therapy in a high-risk patient

After weight gain and reduced activity following CPET-1, CPET-2 showed a new subclinical cardiac dysfunction pattern with a 24% decline in Peak VO₂. The case turns a Green-to-Yellow risk shift into a concrete prevention target: rebuild structured exercise before risk becomes clinically apparent

New symptoms after medication changes and disease progression prompted a tailored management plan with near-term physiologic goals for clinician review

Exercise limitation in CPET-1 was due to chronotropic incompetence. The low dose beta-blocker was stopped and repeat CPET-2 at 5 weeks later revealed clear LV dysfunction. Patient subsequently had statin dose increased and was started on Ranolazine as her new angina regimen

In a high-risk patient, worsening CPET-derived cardiac function supported intensifying risk-modification therapy. The case also shows why Peak VO₂ alone can be misleading: stable Peak VO₂ with lower Peak O₂-pulse (SV) and higher peak HR signals disease progression

After high CACS prompted medical therapy following CPET-1, CPET-2 at 15 months showed physiologic progression and the patient required PCI shortly thereafter. The case illustrates how serial Peak VO₂ can provide a dynamic functional readout that complements anatomy-based calcium scoring

This public teaching case is one of the few documented examples of a favorable CPET response after 9 months of CPAP treatment for sleep apnea. It shows how serial exercise physiology can capture functional improvement after treating a sleep-related cardiovascular stressor

After CPET-1, this firefighter used his ExRx to set goals, lose weight, and increase fitness, with estimated all-cause mortality risk falling by more than 50% one year later. Occupational Medicine and Corporate Wellness programs can expect similar results when employees are motivated

After routine specialist evaluation for symptoms did not identify the cause, his workplace CPET picked up a coronary artery disease pattern. Follow-up found obstructive CAD, leading to coronary stent placement (PCI) with symptom improvement

Annual CPET gave this patient a clear physiologic target for lifestyle change. Determined not to go on blood pressure medications, the firefighter dramatically changed his diet and used the ExRx to lose weight to achieve optimal (green) CV status by CPET-3

This is a case of super-fitness with Peak VO₂ almost twice predicted and completely normal LV function. Notice there is no plateau in VO₂ at peak, indicating that VO₂-max has not been reached and further increase is possible

Highly motivated individual in high-risk category (red) with new symptoms was motivated to turn his CV health around before it was too late. He used the ExRx along with aggressive medical therapy to avoid serious near term complications

Baseline CPET-1 showed a physiologic pattern consistent with microvascular dysfunction in the setting of post-COVID. CPET-2 showed a successful response with a 29% increase in Peak VO₂ after empiric treatment for endothelial dysfunction with L-arginine and Zone 2 exercise

Based on high Peak VO₂ alone, this at-risk individual would appear low risk. But the presence of subclinical cardiac dysfunction placed him at increased risk (yellow). Detailed imaging with coronary CT angiography showed coronary calcification with diffuse non-obstructive CAD driven by abnormal biomarkers. Together, CPET physiology and coronary anatomy highlight how the two tests complement each other

This individual with hyperlipidemia met guideline-based criteria for medical therapy, but CPET placed her in the low-risk (green) category. Cleerly confirmed minimal disease burden. In selected cases like this, CPET-derived physiologic follow-up may support clinician-guided medication timing until cardiac dysfunction appears on subsequent CPET

Even a very high Peak VO₂ can be misleading. Despite reaching 146% predicted, this individual demonstrated a low anaerobic threshold (AT), a microvascular dysfunction pattern and an accelerated BP response at peak exercise, consistent with residual risk and significant room for improvement

CPET can reveal subclinical ischemic heart disease patterns that may contribute to atrial fibrillation risk. Earlier recognition, paired with aggressive clinician-guided risk-factor modification, may help reduce the growing AFib burden at the population level